SEC Comment Letter 0000000000-23-006736 to Aravive, Inc. (CIK 0001513818)
Aravive, Inc. (CIK 0001513818)
Date: June 23, 2023 · CIK: 0001513818 · Accession: 0000000000-23-006736
AI Filing Summary & Sentiment
File numbers found in text: 333-272775
Letter
United States securities and exchange commission logo June 23, 2023 Gail McIntyre President and Chief Executive Officer Aravive, Inc. River Oaks Tower 3730 Kirby Drive, Suite 1200 Houston, TX 77098 Re:Aravive, Inc. Registration Statement of Form S-3 Filed June 20, 2023 File No. 333-272775 Dear Gail McIntyre: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Leslie Marlow
Show Raw Text
United States securities and exchange commission logo
June 23, 2023
Gail McIntyre
President and Chief Executive Officer
Aravive, Inc.
River Oaks Tower
3730 Kirby Drive, Suite 1200
Houston, TX 77098
Re:Aravive, Inc.
Registration Statement of Form S-3
Filed June 20, 2023
File No. 333-272775
Dear Gail McIntyre:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Leslie Marlow